Keytruda 100 MG/4 ML vial 4ML
Ended Awarded
- Contract number
- SPE2DB26FYM41
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $57,327
Award facts
- Contract value 100% obligated
- $57,326.92 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency (DLA) awarded a delivery order valued at $57,327 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois, for the supply of Keytruda 100 mg/4 mL vials. The contract is structured as a firm fixed-price delivery order with no set-aside designation, reflecting the vendor's competitive capability in unrestricted federal procurement. The award was issued on October 27, 2025, with an ultimate completion date of November 18, 2025, and performance will occur at the vendor's Park Ridge facility.
This delivery order is issued under DMS Pharmaceutical Group's Indefinite Delivery Contract (IDC) with the DLA's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, a $30.3 billion acquisition strategy designed to establish regional prime vendor contractors supporting Department of Defense healthcare operations worldwide. The underlying PPV-G GEN V contract, awarded on November 13, 2025, carries a ceiling value of $499,999,999 with a completion date of December 31, 2036, and authorizes the DLA to issue firm fixed-price delivery orders for a comprehensive range of pharmaceutical products including branded and generic prescription drugs, biologics, and medical consumables. DMS Pharmaceutical Group's established performance across multiple therapeutic categories and product lines, including oncology treatments and specialty pharmaceuticals, demonstrates its capability to fulfill the diverse medical supply requirements of military healthcare facilities.
Quick answers
Who was awarded contract SPE2DB26FYM41?
SPE2DB26FYM41 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on October 27, 2025.
How much is contract SPE2DB26FYM41 worth?
The government has obligated $57,327 on SPE2DB26FYM41.
Is contract SPE2DB26FYM41 an order under another contract?
Yes. SPE2DB26FYM41 is a delivery order under SPE2DB22D9316, an indefinite delivery contract.
Was contract SPE2DB26FYM41 competed?
The extent of competition for SPE2DB26FYM41 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award